Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases
- Partnership will expand Evotec's molecular patient database in the area of metabolic diseases and in particular obesity
- Evotec will leverage its leading PanOmics technologies for the generation of large omics data sets including transcriptomics, proteomics and metabolomics
- Lille University Hospital will provide human biological samples and associated clinical data from its ABOS Biobank and will collect specific human biosamples for the collaboration
- All parties will jointly identify and validate novel key mechanisms of obesity & other metabolic diseases based on human data sets
- 此项合作将扩展Evotec的分子患者数据库,在代谢疾病特别是肥胖症领域开展。
- Evotec将利用其领先的PanOmics技术生成大型组学数据集,包括转录组学、蛋白组学和代谢组学。
- 李尔大学医院将提供其ABOS生物库中的人体生物样品和相关临床数据,并收集特定的人体生物样品用于合作。
- 所有参与方将联合识别和验证肥胖症和其他代谢疾病的新关键机制,基于人类数据集。
HAMBURG, GERMANY / ACCESSWIRE / May 30, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the Company entered a partnership with Inserm, the French National Institute of Health and Medical Research, Lille University Hospital and Inserm Transfert (the private subsidiary of Inserm) to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases.
德国汉堡/ACCESSWIRE/2024年5月30日/Evotec SE(法兰克福证券交易所:EVT,MDAX/TecDAX,ISIN:DE0005664809;纳斯达克:EVO)今天宣布,该公司与法国国家卫生和医学研究所(Inserm)、李尔大学医院和Inserm转化(Inserm的私有子公司)建立合作关系,以识别肥胖症和代谢疾病中的新治疗靶点和诊断和预后标志物。
Lille University Hospital is the sponsor of the clinical study entitled ABOS / DIABOMICS (Biological Atlas of Severe Obesity). In the framework of this study, started in 2012, Lille University Hospital develops and maintains the ABOS Biobank composed of a biobank and different associated databases dedicated to the study of obesity and its comorbidities.
李尔大学医院是名为ABOS / DIABOMICS(严重肥胖的生物图谱)的临床研究的赞助方。在这项于2012年开始的研究框架内,Lille大学医院开发和维护了由生物库和各种相关数据库组成的ABOS生物库,专门用于研究肥胖症及其并发症。
Obesity, a medical condition characterised by an excess accumulation of fat cells and uncontrolled ectopic fat deposition in the body, is currently recognised as one of the most important public health problems. It is estimated that over one billion adults globally will be affected by 2030. The strategic partnership between Evotec, Inserm, Lille University Hospital and Inserm Transfert aims at identifying novel multi-modality therapeutic targets. Evotec will gain access to a large patient cohort with severe obesity for the longitudinal assessment of metabolic outcomes after bariatric surgery-induced weight loss. The cohort consists of more than 8,000 human samples. Evotec will support the recruitment of 200 additional subjects within the next two years.
肥胖症是一种由于脂肪细胞过度积累和不受控制的体内异位脂肪沉积而特征化的医疗状况,目前被认为是最重要的公共卫生问题之一。据估计,到2030年,全球有超过10亿成年人受到影响。Evotec、Inserm、Lille大学医院和Inserm转化之间的战略合作旨在找到新的多模式治疗靶点。Evotec将获得一个重度肥胖症患者队列,以评估减重术诱导体重损失后代谢结局的长期评估。该队列由超过8,000个人样本组成。Evotec将在未来两年内支持招募200名额外的被试者。
Under the agreement, Lille University Hospital will provide human biological samples and associated clinical data from its ABOS biobank and will collect specific human biological samples for the collaboration. Evotec will perform various omics studies on cohort samples to generate large omics data sets including transcriptomics, proteomics, and metabolomics data to better understand the etiology of metabolic diseases like metabolic dysfunction-associated steatohepatitis ("MASH"), obesity, diabetes, and cardiovascular disease. These PanOmics data will feed into Evotec's proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data. The data will be analysed by all parties to identify and validate key mechanisms of obesity and other metabolic diseases.
根据协议,李尔大学医院将提供其ABOS生物库中的人体生物样品和相关临床数据,并收集特定人类生物样品进行合作。Evotec将对群体样本进行各种组学研究,生成包括转录组学、蛋白质组学和代谢组学数据在内的大型组学数据集,以更好地理解代谢疾病的病因,如代谢功能障碍相关脂肪肝(“MASH”)、肥胖症、糖尿病和心血管疾病等等。这些组学数据将被纳入Evotec的专有转化分子患者数据平台E.MPD,该平台作为分子患者数据的中央数据仓库。所有参与方将分析这些数据,以识别和验证肥胖症和其他代谢疾病的关键机制。
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are excited to enter this partnership with Inserm and Lille University Hospital accessing a cohort of obese patients that is extremely well characterised. Currently over 40% of the US population suffers from obesity. The condition is a major health threat as it is connected to a plethora of other medical conditions such as type 2 diabetes, hypertension, cardiovascular disease, congestive heart failure, kidney disease and non-alcoholic fatty liver disease. This collaboration will help to understand obesity as a disease, something not achieved despite recent breakthroughs. Expanding our understanding of the key molecular mechanisms driving disease progression will allow us to identify and develop more effective but also safer treatment options than currently available."
Evotec首席科学官Cord Dohrmann博士评论道:“我们很高兴与Inserm和Lille大学医院建立这种合作关系,可以获得极其充分的肥胖症患者队列。目前,超过40%的美国人口患有肥胖症。由于与2型糖尿病、高血压、心衰、肾脏疾病和非酒精性脂肪肝病等多种疾病存在关联,因此肥胖症是一种重大的健康威胁。尽管取得了最近的突破,但仍未能理解肥胖症作为一种疾病的本质。扩大对推动疾病进展的关键分子机制的理解,将使我们能够确定并开发比当前可用的更有效,更安全的治疗选择。”
Prof. Francois Pattou, Translational Research Laboratory for Diabetes, Inserm UMR 1190 (under the joint supervision of Inserm, University of Lille and Lille University Hospital), PhD at Lille University Hospital, and Chairman of the Scientific Committee of Lille University Hospital ABOS Biobank, added: "Collaborating on cutting-edge science with a human data-centric approach gives us a unique opportunity to discover novel treatments for the benefit of patients living with obesity and metabolic diseases. The strong know-how and capabilities from Evotec will enable us to further strengthen and advance our research efforts within obesity and metabolic diseases based on human-relevant biology, to contribute to our overall mission of improving human health for all."
Lille大学和Lille大学医院翻译研究实验室糖尿病转化研究教授,Inserm UMR 1190(Inserm、Lille大学和Lille大学医院联合监督),Lille大学医院ABOS生物库科学委员会主席,博士Francois Pattou补充道:“与以人为中心的数据为基础的尖端科学合作,为我们提供了探索为患有肥胖和代谢疾病的患者发现新治疗方法的独特机会。Evotec的强大专业知识和能力将使我们能够进一步加强和发展基于以人类为基础的肥胖和代谢疾病的研究,以促进我们对改善所有人类健康的总体使命的贡献。”
Prof. Bart Staels, Nuclear receptors, cardiovascular diseases and diabetes Laboratory, Inserm UMR 1011 (under the joint supervision of Inserm, Lille University Hospital, University of Lille and Institut Pasteur of Lille), said: "We are very excited about the collaboration and are confident that the combination of Evotec's excellent expertise and our commitment to therapeutic innovation, translational research, and multidisciplinary approaches, will open up new possibilities in discovery and development of novel drugs targeting obesity and metabolic diseases, with the potential to make a difference for patients living with these conditions."
Inserm UMR 1011(Inserm、Lille大学医院、Lille大学和法国里尔巴斯德研究所联合监督)核受体、心血管疾病和糖尿病实验室的Bart Staels教授表示:“我们对此合作感到非常兴奋,并相信Evotec的出色专业知识和我们对治疗创新、转化研究和多学科方法的承诺将为发现和开发针对肥胖症和代谢疾病的新药物打开新的可能性,对生活中患有这些疾病的患者产生积极影响。”
Noémie Pellegrin, Director of Industry Partnerships and Entrepreneurship of Inserm Transfert, adds: We are delighted with this research partnership, which capitalises on the wealth of know-how within the Inserm laboratories, the quality data from Lille University Hospital and the cutting-edge molecular translational technologies developed by Evotec. This collaboration will advance our understanding of obesity and associated metabolic diseases through the identification of key molecular mechanisms and new therapeutic targets.
Inserm Transfert的产业合作和创业负责人Noémie Pellegrin补充说:“我们对这个研究合作非常高兴,它发挥了Inserm实验室的丰富专业知识,来自Lille大学医院的高质量数据和Evotec开发的前沿分子转化技术。这种合作将通过在人类分子的背景下识别关键分子机制和新的治疗靶点来推动我们对肥胖症和相关代谢疾病的理解。”
About Obesity
Obesity is defined as abnormal or excessive fat accumulation that presents a risk to health. A body mass index ("BMI") over 30 is obese. However, BMI categories for defining obesity vary by age and gender in infants, children, and adolescents. The issue has grown to epidemic proportions and obesity constitutes a major public health challenge that undermines social and economic development. The worldwide prevalence of obesity nearly tripled between 1975 and 2016. The World Obesity Federation estimates that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Once associated with high-income countries, obesity is now also prevalent in low-and middle-income countries, including among lower socio-economic groups. Overweight and obesity are caused by many factors including behaviours like eating patterns, lack of sleep or physical activity, and some medicines, as well as genetics and family history. Obesity is a chronic health condition that raises the risk for heart disease and is linked to many other health problems, including MASH, type 2 diabetes and cancer.
关于肥胖症
肥胖症被定义为脂肪异常或过度积累,存在健康风险。BMI超过30即为肥胖。然而,在婴幼儿、儿童和青少年中,BMI类别的定义肥胖程度因年龄和性别而异。这个问题已经成为流行病,肥胖构成了一个重大的关乎社会和经济发展的公共卫生挑战。肥胖的全球患病率在1975年至2016年间几乎翻了三倍。据世界肥胖联盟估计,2020年全球大约有7.7亿成年人患有肥胖症,预计到2030年这一数字将超过10亿。超重和肥胖的原因包括行为(如饮食、缺乏睡眠或体育锻炼),以及一些药物,以及遗传和家族史。肥胖是一种慢性健康状况,它增加了患心脏病的风险,与许多其他健康问题有关,包括MASH、2型糖尿病和癌症等等。
About E.MPD
E.MPD, Evotec's translational molecular patient database, is one of the largest and highest quality molecular databases globally. Evotec's integrated technology platforms show that the best way to effectively treat disease is to identify underlying disease mechanisms and find the most suitable therapy on the basis of molecular data guiding all experimental processes towards early disease relevance. Therefore, data aggregation, integration, and the precise analysis of data is the critical path to effective and affordable medicine in the future.
关于E.MPD
E.MPD是Evotec的转化分子患者数据库之一,也是全球最大、最高质量的分子数据库之一。Evotec的集成技术平台表明,有效治疗疾病的最佳方法是确定潜在的疾病机制,并基于分子数据找到最适合的治疗方案,引导所有实验过程朝着早期疾病相关性的方向发展。因此,数据的汇总、集成和精确的分析是未来有效和经济医学的关键路径。
E.MPD serves as the backbone for data-driven partnerships that will lead to innovative new medicines, better patient stratification, and potentially pave the way towards a new paradigm of more effective diagnostic and preventative healthcare. Through gathering and analysing patient-derived data in combination with AI/ML tools, Evotec is also able to better predict both safety and efficacy indicators in drug development.
E.MPD是以数据为基础的合作关系的支柱,这些关系将导致创新的新药物、更好的患者分层,并有可能开辟一条通向更有效的诊断和预防保健的新范式之路。通过通过结合人类数据和AI/ML工具,收集并分析患者源数据,Evotec还能更好地预测药物开发中的安全性和有效性指标。
About Inserm
Founded in 1964, Inserm is a public scientific and technological institute which operates under the joint authority of the French Ministries of Health and Research. The institute is dedicated to biomedical research and human health, and is involved in the entire range of activities from the laboratory to the patient's bedside. It also partners with the most prestigious research institutions in the world that are committed to scientific challenges and progress in these fields.
关于Inserm
Inserm成立于1964年,是一个公共的科学技术研究所,受法国卫生和研究部的联合管理。该研究所致力于生物医学研究和人类健康,涉及从实验室到病床的整个范围的活动。它还与全球最着名的研究机构合作,致力于这些领域的科学挑战和进展。
About Lille University Hospital
With over 16,000 professionals and 10 hospitals on a single campus, the Centre Hospitalier Universitaire de Lille is one of the four largest university hospital centers in France, and one of the largest in Northern Europe. As a regional referral centre as well as teaching, innovation and research hospital, it serves the 6 million inhabitants of the Hauts-de-France region. Lille University Hospital is strongly committed to the development of therapeutic innovation and clinical research. Its research strategy focuses on the early diagnosis and treatment of multi-factorial diseases, including cancer, neuroscience, cardiovascular, metabolic, inflammatory and infectious pathologies. For further information: , X/Twitter and LinkedIn.
关于Lille大学医院
作为地域板块之一,里尔大学医院集团拥有超过16000名专业人士和10家医院。作为地区转诊中心、教学、创新和研究医院,里尔大学医院集团为上法兰西大区的600万居民提供医疗服务。里尔大学医院集团致力于医疗创新和临床研究的发展。其研究策略主要集中在多因素疾病的早期诊断和治疗上,包括癌症、神经科疾病、心血管、代谢、炎症和感染病理学。若需了解更多信息,请参阅:, X/Twitter和页面。LinkedIn.
About Inserm Transfert
Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), is responsible for value creation of Inserm and its academic partners' innovations in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000, and manages, under a Public Service Management Contract (Concession de Service Public) the entire innovation value chain and the transfer of knowledge from Inserm's research laboratories to industry, from invention disclosure to industrial partnerships and startups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases and cohorts. For more information:
关于Inserm Transfert
Inserm Transfert是法国国家卫生和医学研究所(Inserm)的私人子公司,负责增值Inserm及其学术合作伙伴创新的人类健康,并推广符合国际最佳实践的长期技术转移。Inserm Transfert SA成立于2000年,根据公共服务管理合同(Concession de Service Public)管理整个创新价值链和知识转移,从发明披露到工业伙伴关系和创业公司的成立。Inserm Transfert还提供有关建立和管理国家、欧洲和国际项目的服务,以及支持临床研究和健康数据/数据库和队列的技术转移。如需了解更多信息,请参阅:
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn.
关于Evotec SE
Evotec是一家生命科学公司,拥有独特的业务模式,实现其发现和开发高效治疗方法并使患者受益的使命。公司的多模态平台包括一系列创新技术、数据和科学,用于发现、开发和生产一类和优秀的药物产品。Evotec为所有20大制药公司和800多家生物技术公司、学术机构以及其他医疗保健利益相关者提供高价值的合作伙伴关系和解决方案。Evotec在一系列目前未得到充分服务的疗法领域有战略性活动,包括神经学、肿瘤学以及代谢和传染性疾病。在这些专业领域内,Evotec旨在创建创新治疗方法的世界领先的合作伙伴关系,并已经建立了一个由200多个独有和合有的研发项目组成的组合,从早期发现到临床开发。Evotec在全球拥有超过5000名高素质人才。该公司在欧洲和美国的网站提供高度协同的技术和服务,并作为完善的卓越簇群运营。欲了解更多信息,请查看 并关注我们的X/Twitter @EvotecForward-looking-statements 和LinkedIn.
Forward-looking-statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
本公告包含关于未来事件的前瞻性声明,包括Evotec证券的招股说明。其包括对Evotec营收、集团EBITDA和未合作的研发费用的预期评论。这些前瞻性声明基于Evotec在发表这些声明时可获得的信息和预期和假设,且Evotec认为这属于合理范围内。不能保证这些预期将证明是正确的。这些声明涉及已知和未知风险,并且基于一些假设和估计,这些假设和估计具有显著不确定性和偶发事件,其中许多超出了Evotec的控制范围。Evotec明确否认任何公开披露任何更新或修订此类前瞻性声明的义务或承诺,以反映此类声明基于的任何期望或任何事件、状况或环境的任何变化。
SOURCE: Evotec SE
For further information, please contact:
如需更多信息,请联系:
Media
媒体
Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com
Gabriele Hansen
全球企业传媒高级副总裁
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com
Hinnerk Rohwedder
全球企业传媒董事
Hinnerk.Rohwedder@evotec.com
Investor Relations
投资者关系
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
Volker Braun
全球投资者关系与esg高级执行副总裁
Volker.Braun@evotec.com
SOURCE: Evotec SE
来源:Evotec SE